S-4220-119
Committee on Veterans' Affairs. Hearings held.
Sponsored by Tim Sheehy (R-MT)
What it does
This bill would establish an Office of Novel Therapeutics within the Veterans Health Administration (VHA) to coordinate the evaluation, research, and potential implementation of emerging mental health treatments — including therapies currently under FDA review such as psychedelic-assisted therapies. It would also create a Clinical Implementation Program to test these treatments at designated VA medical centers, establish centers of excellence, form a veteran advisory committee, and require the VA Secretary to submit a national preparedness strategy to Congress within 180 days of enactment and annual progress reports thereafter.
Who benefits
Veterans suffering from PTSD, treatment-resistant depression, substance use disorders, suicidality, traumatic brain injury, chronic pain, and related conditions — particularly those who have not responded to existing treatments. VA clinicians and peer support specialists who would receive new training and credentialing frameworks. Academic and research institutions affiliated with the VA that would gain new coordination and funding pathways. Veterans' families and caregivers who would have representation on the advisory committee. Communities near VA centers of excellence that could see expanded mental health infrastructure.
Who is hurt
VA facilities and staff who would bear implementation burdens — including facility modifications, workforce retraining, and protected clinical time requirements — without guaranteed dedicated funding in the bill text. Pharmaceutical companies developing conventional mental health treatments may face increased competition if novel therapies prove effective. Veterans in rural or underserved areas may experience uneven access if centers of excellence are concentrated in larger VA medical centers. Taxpayers who would bear costs of new administrative infrastructure, though the bill does not specify appropriations amounts.
Supporters argue
Supporters argue that veteran suicide rates remain at roughly 17 per day and that existing treatments leave a significant portion of veterans with PTSD and depression without adequate relief, citing VA and DoD research showing treatment-resistant cases are common. They contend that proactive infrastructure planning — before FDA approval of novel therapies — is essential to avoid the delays and inconsistent access that have historically followed new treatment approvals, and that the VA's integrated care model makes it uniquely suited to deliver the intensive, multi-session protocols these therapies require.
Opponents argue
Opponents argue that the bill creates a permanent administrative bureaucracy around therapies that have not yet received FDA approval — most notably MDMA-assisted therapy, which the FDA declined to approve in 2024 citing insufficient evidence — raising concerns about institutional momentum toward treatments whose safety and efficacy remain unproven at scale. They contend that resources spent building infrastructure for speculative therapies could be redirected to expanding access to evidence-based treatments already shown to help veterans, and that the bill's broad definition of "emerging therapeutic intervention" gives the new office wide discretionary authority with limited congressional oversight.